Frank Pallone

“ To support research related to combating antimicrobial resistance and antibiotic resistant bacteria, including research into new treatments, diagnostics, and vaccines, research, in consultation with the Centers for Disease Control and Prevention, into stewardship, and the development of strategies, in coordination with the Biomedical Advanced Research and Development Authority under section 319L of the Public Health Service Act, to support commercialization of new antibiotics, not to exceed a total of $1,144,500,000, as follows: “ (I) For each of fiscal years 2022 through 2025, $100,000,000. ”

“ Eligible Entity.—In this section, the term ‘eligible entity’ means an entity receiving funding under— “ (1) the Small Business Innovation Research program of the National Institutes of Health; or “ (2) the Small Business Technology Transfer program of the National Institutes of Health. “ (c) Use Of Funds.—An eligible entity shall use the funds received through such grant or contract to support— “ (1) the Commercialization Readiness Pilot program of the National Institutes of Health; “ (2) the Innovation Corps program of the National Institutes of Health ”

“ Eligible Entities.—To be eligible to receive assistance under the pilot program established under subsection (a) , an entity shall— “ (1) be seeking to market a medical product or therapy that is the subject of clinical trial or trials to be supported using such assistance ”